German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

Goethe University

Status and phase

Completed

Phase 4

Conditions

Adult Acute Lymphocytic Leukemia

Treatments

Drug: 6-Mercaptopurine

Drug: VM26

Drug: Daunorubicin

Drug: Cytarabine

Drug: Methotrexate

Procedure: Mediastinal irradiation (if residual tumor)

Drug: VP16

Procedure: stem cell transplantation

Procedure: CNS irradiation

Drug: Ifosfamide

Drug: G-CSF

Drug: Cyclophosphamide

Drug: Adriamycin

Drug: Asparaginase

Drug: Dexamethasone / Prednisolone

Drug: Fludarabine

Drug: Vincristine / Vindesine

Drug: Idarubicin

Drug: Thioguanine

Study type

Interventional

Funder types

Other

Identifiers

NCT00199056

GMALL10

Details and patient eligibility

About

The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for patients with high and very high risk of relapse. Patients with standard risk receive further consolidation and reinduction chemotherapy. In parallel minimal residual disease (MRD) is evaluated. A MRD based risk stratification and treatment decision is developed.

Sex

All

Ages

15 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria